The Novavax COVID Vaccine Has Been Approved
The FDA has approved Novavax’s Nuvaxovid, a non-mRNA COVID vaccine aimed at adults 65 and high-risk individuals aged 12-64. Although the approval is limited, many people qualify due to underlying conditions. Nuvaxovid offers an effective alternative, with simpler storage and fewer side effects compared to other vaccines.
The Novavax COVID Vaccine Has Been Approved Read More »
You must be logged in to post a comment.